Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
During this window, substances applied to the skin surface can penetrate directly to the dermis at concentrations that approach injectable delivery
NAD+ enhances cellular energy production and often reduces fatigue during GLP-1/GIP therapy
Moisturises and Conditions: This vitamin prevents dryness from your scalp and keeps it moisturised by supporting the supply of oxygen to your scalp
A clinical study in the European Journal of Nutrition (2011) confirmed that 1,000 mg/day for four weeks produced no significant changes in oxidative stress biomarkers
